FDA Approved Pfizer’s Vyndaqel and Vyndamax
It is the first medicine for the rare heart disease, transthyretin mediated amyloidosis, to get approval in the U.S.
https://blog.genexi.ru/news/FDA-Approved-Pfizers-Vyndaqel-and-Vyndamax-en
It is the first medicine for the rare heart disease, transthyretin mediated amyloidosis, to get approval in the U.S.
https://blog.genexi.ru/news/FDA-Approved-Pfizers-Vyndaqel-and-Vyndamax-en